suck pdf from google scholar
unlimited free pdf from europmc21051951    free
PDF from PMC    free
html from PMC    free
PDF vom PMID21051951  :  Publisher
suck pdf from library genesis
English Wikipedia

Nephropedia Template TP (

Twit Text

  • DeepDyve
  • Pubget Overpricing

  • lüll
  • Antibody-based therapeutics to watch in 2011
  • Reichert JM
  • MAbs 2011[Jan]; 3 (1): 76-99
  • This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates, recently published clinical study results and on-going Phase 3 studies. In alphanumeric order, the 2011 therapeutic antibodies to watch list comprises AIN-457, bapineuzumab, brentuximab vedotin, briakinumab, dalotuzumab, epratuzumab, farletuzumab, girentuximab (WX-G250), naptumomab estafenatox, necitumumab, obinutuzumab, otelixizumab, pagibaximab, pertuzumab, ramucirumab, REGN88, reslizumab, solanezumab, T1h , teplizumab, trastuzumab emtansine, tremelimumab, vedolizumab, zalutumumab and zanolimumab. In alphanumeric order, the 2011 Fc fusion protein therapeutics to watch list comprises aflibercept, AMG-386, atacicept, Factor VIII and Factor IX-Fc. Commercially-sponsored mAb and Fc fusion therapeutics that have progressed only as far as Phase 2/3 or 3 were included. Candidates undergoing regulatory review or products that have been approved may also be in Phase 3 studies, but these were excluded. Due to the large body of primary literature about the candidates, only selected references are given and results from recent publications and articles that were relevant to Phase 3 studies are emphasized. Current as of September 2010, the information presented here will serve as a baseline against which future progress in the development of antibody-based therapeutics can be measured.
  • |*Clinical Trials, Phase III as Topic[MESH]
  • |Antibodies, Monoclonal/*therapeutic use[MESH]
  • |Humans[MESH]
  • |Recombinant Fusion Proteins/*therapeutic use[MESH]
  • |Treatment Outcome[MESH]

  • *{{pmid21051951}}
    *<b>[ Antibody-based therapeutics to watch in 2011 ]</b> MAbs 2011; 3(1) ; 76-99 Reichert JM


    Nephropedia PMID record

    Deutsche Wikipedia - im Artikel

    Hier den unten stehenden Textblock hineinkopieren


    76 1.3 2011